# MODERNA INC.


ISIN: **US60770K1079** WKN: 60770K107 Asset Class: Stock

Company 2024/04/16 22:00:00 **Price** moderna 103.79 USD **Difference** -0.07%(-0.07)

**Contact Details** 

MODERNA INC. Tel: +1-617-714-6500 Fax: +617-583-1998

200 Technology Square Web: http://www.modernatx.com 02139 Cambridge E-mail: info@modernatx.com



### **Company Profile**

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

#### Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	10,325,000,000		13,431,000,000		16,071,000,000	
Common stock capital		0		0		0
Fixed assets	8,101,000,000		12,656,000,000		8,798,000,000	
Equity capital of a company		13,854,000,000		19,123,000,000		14,145,000,000
Cash and cash equivalents	2,924,000,000		3,205,000,000		6,848,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		3,015,000,000		4,923,000,000		9,128,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,557,000,000		2,041,000,000		1,596,000,000
Different income		-		-		-
Other liabilities		339,000,000		808,000,000		691,000,000
Total assets	18,426,000,000	18,426,000,000	26,087,000,000	26,087,000,000	24,869,000,000	24,869,000,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	5,600	3,900	2,700
Equity ratio	75.19%	73.30%	56.88%
Debt-equity ratio	33.00%	36.42%	75.81%

#### **Others**

	2023	2022	2021
Tax Expense Rate	-19.58%	12.67%	8.15%

# **MODERNA INC.**

ISIN: US60770K1079 WKN: 60770K107 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	6,840,000,000	19,109,000,000	18,413,000,000
Net income	-4,714,000,000	8,362,000,000	12,202,000,000
EBIT	-4,062,472,500	8,833,177,200	12,478,600,500
Operating income before taxes	-3,942,000,000	9,575,000,000	13,285,000,000
Cash Flow	-3,118,000,000	4,981,000,000	13,620,000,000
Net interest income	383,000,000	171,000,000	0
Research and development expenses	4,224,000,000	2,947,000,000	1,759,000,000
Income taxes	772,000,000	1,213,000,000	1,083,000,000
Result from investments in subsidaries, associates and other	-	-	0
Revenues per employee	1,147,288	4,602,329	6,405,678

# **Board of Directors**

Members of Management Board		
Noubar Afeyan	Chairman of Board of Directors	
Elizabeth Nabel	Member of Board of Directors	
Francois Nader	Member of Board of Directors	
Robert Langer	Member of Board of Directors	
Sandra Horning	Member of Board of Directors	
Elizabeth Tallett	Member of Board of Directors	
Paul Sagan	Member of Board of Directors	
Stephen Berenson	Member of Board of Directors	
Stéphane Bancel	Chairman of Managing Board	
Corinne Le Goff	Member of Executive Committee	
David Meline	Member of Executive Committee	
Juan Andres	Member of Executive Committee	
Kate Cronin	Member of Executive Committee	
Marcello Damiani	Member of Executive Committee	
Paul Burton, M.D.	Member of Executive Committee	
Shannon Thyme Klinger	Member of Executive Committee	
Stephen Hoge, M.D.	Member of Executive Committee	
Tracey Franklin	Member of Executive Committee	